NJ-LABVANTAGE
LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, today announced the launch of version 8.8 of its industry-leading LabVantage LIMS platform.
LabVantage 8.8 includes multiple enhancements throughout every element of the platform. Together, they improve the accuracy, speed, usability, and security of LabVantage’s LIMS components, including its integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics.
“LabVantage 8.8 exemplifies our dual commitment to both major upgrades to our flagship LIMS platform and to continuous improvements, with the goal of providing our customers with an ever easier, safer, smarter, more flexible and more reliable system that enables the digital transformation of their laboratory,” said Mikael Hagstroem, Chief Executive Officer at LabVantage Solutions. “Over the past several years, we have added major components to our LIMS platform, including options such as SDMS, artificial intelligence (AI)-based analytics, and validated enterprise SaaS. Complementing these is our continuing attention to strengthening every aspect of the user experience, as is evident in version 8.8. For example, our new intelligent laboratory approvals substantially improve the speed and efficiency of data reviews, helping our large and diverse customer base advance towards the smart lab of the future.”
LabVantage 8.8 is available to support the more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food and beverage, consumer packaged goods, oil & gas, genetics/diagnostics, forensic, and healthcare industries that rely on the LabVantage platform.
Notable among the many improvements and enhanced capabilities in LabVantage 8.8 are the following:
- Intelligent Approvals – This new capability uses rules-based AI to streamline and speed data reviews. Reviewing large volumes of data in the LIMS is time-consuming and cumbersome. Version 8.8 enables manual approvals by exception only, allowing automatic approvals when there are no exceptions. This new feature allows users to increase the speed and efficiency of their operations against the backdrop of an ever-increasing data load.
- Automatic Redo Calculations – Users may forget to manually re-calculate values, which affects not only final, but intermediate calculations, and can have a multi-level downstream effect on accuracy. The enhanced feature automatically triggers re-calculation when a reference is modified, allowing users to focus on the task at hand, while improving accuracy and data quality.
- Enhanced Cybersecurity – LabVantage 8.8 provides enhanced security against OWASP Top 10 threats, and includes 3rd party certification of testing. A widely accepted standard for web application developers, OWASP Top 10 represents a broad consensus about critical cybersecurity risks. These additional safeguards incorporated in LabVantage 8.8 represent further improvements to security, providing greater peace of mind to users.
- Accessibility – As part of ongoing efforts to better serve all of its customers, LabVantage 8.8 contains features for improved compliance with the Web Content Accessibility Guidelines (WCAG) international standard, Section 508, intended to facilitate access to the platform for users who have visual or other accessibility problems. The improved version of LabVantage Portal now has a certification of WCAG compliance, documenting a number of new features that provide increased accessibility.
LabVantage is known for its exceptional customer service and the LabVantage Professional Services team is ready to help users maximize the value of the version 8.8 enhancements.
For more information on LabVantage LIMS 8.8 click here, or email info@labvantage.com.
About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. The LabVantage informatics platform is highly configurable, integrated across a common architecture, and 100% browser-based to support hundreds of concurrent users. Deployed on-premise, via the cloud, or SaaS, it seamlessly interfaces with instruments and other enterprise systems – enabling true digital transformation. The platform consists of the most modern laboratory information management system (LIMS) available, integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics; and, for healthcare settings, a laboratory information system (LIS). We support more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food & beverage, consumer packaged goods, oil & gas, genetics/diagnostics, forensic, and healthcare industries. Headquartered in Somerset, NJ, with global offices, LabVantage has offered its comprehensive portfolio of products and services to enable customers to innovate faster in the R&D cycle, improve manufactured product quality, achieve accurate record-keeping, and comply with regulatory requirements for four decades. For more information, visit labvantage.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221207005025/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2026 Japan Prize: Two U.S. Scientists and One Japanese Scientist Awarded26.1.2026 15:00:00 CET | Press release
Presentation Ceremony to Take Place in Tokyo in April The Japan Prize Foundation announced the winners of the 2026 Japan Prize at 1:00 p.m. on 21 January 2026. Prof. Cynthia Dwork (USA) has been awarded the Japan Prize in the field of Electronics, Information, and Communication. Prof. Shizuo Akira (Japan) and Prof. Zhijian "James" Chen (USA) have been awarded the Japan Prize in the field of Life Sciences. For this year’s Japan Prize, Prof. Dwork is being recognized for her Contribution to leading research for building an ethical digital society, including differential privacy and fairness. Prof. Akira and Prof. Chen are being recognized for their Discovery of the nucleic acid sensing mechanism by the innate immune system. For the 2026 Japan Prize, the Foundation asked approximately 16,000 prominent scientists and engineers from around the world to nominate researchers working in this year’s fields. We received 107 nominations for the field of Electronics, Information, and Communication
Uzbekistan, the Engine of Central Asia: GDP Above USD 145 Billion and Exports Rising to USD 33.4 Billion – Embassy of the Republic of Uzbekistan in Italy26.1.2026 14:31:00 CET | Press release
With a GDP exceeding USD 145 billion, exports of USD 33.4 billion up 23 percent, and gold reserves surpassing USD 60 billion, Uzbekistan enters 2026 with solid and steadily strengthening macroeconomic indicators. The Embassy of the Republic of Uzbekistan in Italy claims that the climate of confidence, reaffirmed in the State of the Nation Address delivered on 26 December by President Shavkat Mirziyoyev, is reflected in international trade data: total foreign investment has reached USD 43.1 billion, equal to 31.9 percent of GDP. This trajectory has also contributed to an improvement in the country’s sovereign rating, upgraded to BB by the leading international rating agencies. For the current year, the Government forecasts economic growth of 6.6 percent, with GDP estimated at USD 167 billion. A total of 782 new industrial and infrastructure projects will be launched, with an overall value of USD 52 billion, including 228 large production facilities as early as next year. The focus will
Lucend, Formerly Coolgradient, Raises $3.3M to Bring Transparent AI to Data Centers to Increase Uptime and Reliability While Maximizing Efficiency26.1.2026 14:00:00 CET | Press release
Lucend Seed round led by Remarkable Ventures Climate (RVC) to bring Transparent AI insights to data center operators in the U.S. increasing operational efficiency by 40% Lucend today announced that it is bringing its transparent data center optimization to the U.S. market, helping enterprises illuminate complex operational environments and empowering data center operators, innovation officers, and sustainability officers with the intelligence they need to act with trust, accuracy, and confidence. Lucend’s Transparent AI platform connects to existing infrastructure, no new hardware required, to transform static systems into adaptive, self-learning environments. The software takes existing sensor data to see connections across 300 billion sensor readings. Lucend’s AI analyzes billions of data points daily and provides prescriptive recommendations. The intelligence that Lucend’s platform delivers “shows its work,” empowering operators and delivering verifiable impact across enterprise env
Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-infectious Anterior Uveitis26.1.2026 14:00:00 CET | Press release
Study could lead to first-ever topical steroid-free treatment for the inner eye disease non-infectious anterior uveitis (NIAU) The study builds on ocular pharmacokinetic models demonstrating delivery after topical application and on animal models of experimental uveitis demonstrating pharmacological effects Novaliq is expanding with this proof-of-concept study into retina and inner-eye diseases as targeted topical delivery of EyeSol®-based drugs allowing to develop breakthrough therapies Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique water-free EyeSol® drug category, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NOV05, the company’s first IND for treating inner-eye diseases. NOV05, tacrolimus ophthalmic solution in EyeSol®, is a unique, steroid-free topical anti-inflammatory treatment. The IND clearance enables initiation of the EYETAC Pha
IQM Quantum Computers Appoints Jan Goetz as Sole CEO to Lead Next Phase of Global Growth26.1.2026 10:15:00 CET | Press release
Jan Goetz becomes sole CEO, while Søren Hein is appointed Chief Operating Officer and Deputy CEO. Former Co-CEO Mikko Välimäki transitions out of his commercial role and remains as an advisor until 31 March 2026. This new leadership structure is designed to strengthen IQM's global strategic direction, planning and execution. IQM Quantum Computers, a global leader in full-stack superconducting quantum computers, today announced a transition from its Co-CEO structure to a single Chief Executive Officer model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126737805/en/ From left to right: Jan Goetz (Co-founder & CEO) and Søren Hein (Chief Operating Officer and Deputy CEO) Co-founder and current Co-CEO Dr Jan Goetz becomes sole CEO effective since January 1st, following a resolution passed by the IQM board. In addition, Dr Søren Hein has been appointed Chief Operating Officer and Deputy CEO. As part of the transition, Mikko
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom